A carregar...
Fidaxomicin for the treatment of Clostridioides difficile in children
Fidaxomicin is an oral narrow-spectrum novel 18-membered macrocyclic antibiotic that was initially approved in 2011 by the US FDA for the treatment of Clostridioides difficile infections (CDI) in adults. In February 2020, the FDA approved fidaxomicin for the treatment of CDI in children age >6 mo...
Na minha lista:
| Publicado no: | Future Microbiol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8097504/ https://ncbi.nlm.nih.gov/pubmed/32715754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fmb-2020-0104 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|